Erik Vinther
​

Erik has a master in Business Economics from the University of Aarhus. Erik has during his more than 30 years of experience from the pharmaceutical industry worked the entire product lifespan, from very early development projects to marketed products.​
 

During his tenure at Novo Nordisk he has e.g. been responsible for launch strategy and planning for Wegovy® the first significant obesity product marketed with annual sales of 4.5 bUSD 2 years after launch and for the first time establishing a true medical obesity market. He was responsible for early commercial development for Rybelsus® the world's first oral peptide, leading to a market driven phase 3 programme ensuring launch success, and has further been responsible for the re-launch of Levemir® establishing the product as a general basal insulin for diabetes. As country manager Erik had direct sales and marketing responsibility driving local product launches and sales growth.​

Erik is known for his good collaborative skills with scientific and development colleagues and solid understanding of development challenges which ensures that projects can balance the regulatory and development challenges while moving forward to realize the commercial potential